Alkem Laboratories
Working at Alkem Laboratories
Company Summary
Overall Rating

On-Par with

Highly rated for
Salary
Work Policy




Top Employees Benefits
About Alkem Laboratories

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. Today, with a footprint in 40 countries, 19 manufacturing units, over 800 brands, and many, many milestones later, we have an assemblage of tales enriched with pioneering work. Alkem is one of the biggest names in the generic and speciality pharmaceutical sector in India. Our legacy is a testament to the sheer hard work, perseverance, and grit to take the path with barely any footprints and a lot of latent potential to make a difference. A single step, a single idea, led to Alkem – a journey driven by our commitment to people, innovation, and service to the community.
Consistently ranked amongst the top ten pharmaceutical companies in India, we embrace the responsibility of making a remarkable impact on people’s lives. Our portfolio includes eminent brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst the top 50 pharmaceutical brands in India.
Alkem Laboratories Ratings
Overall Rating
Category Ratings
Salary
Company culture
Work-life balance
Skill development
Work satisfaction
Job security
Promotions
Work Policy at Alkem Laboratories
Alkem Laboratories Reviews
Top mentions in Alkem Laboratories Reviews
Compare Alkem Laboratories with Similar Companies
Change Company | Change Company | Change Company | ||
---|---|---|---|---|
Overall Rating | 3.9/5 based on 2.9k reviews | 4.0/5 based on 5.8k reviews | 4.1/5 based on 6.9k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Salary | Salary Skill development Job security | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | No critically rated category | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 71% employees reported | Work from office 82% employees reported | Work from office 72% employees reported | - |
Rating by Women Employees | 4.0 Good rated by 139 women | 4.0 Good rated by 441 women | 4.1 Good rated by 680 women | - no rating available |
Rating by Men Employees | 3.9 Good rated by 2.5k men | 4.0 Good rated by 5k men | 4.1 Good rated by 5.8k men | - no rating available |
Job security | 3.4 Average | 3.8 Good | 3.7 Good | 4.0 Good |
Alkem Laboratories Salaries
Medical Representative
Senior Officer
Area Business Manager
Officer
Marketing Executive
Regional Manager
Area Sales Manager
Research Associate
Regional Sales Manager
Scientist
Alkem Laboratories Interview Questions
Interview questions by designation
Top Alkem Laboratories interview questions and answers
Alkem Laboratories Jobs
Alkem Laboratories News
SBI Mutual Fund Acquires Additional Shares In Alkem Laboratories For Rs 300 Crore
- SBI Mutual Fund acquired additional shares in Alkem Laboratories for Rs 300 crore through an open market transaction.
- The shares were purchased at an average price of Rs 4,680 apiece, resulting in a transaction value of Rs 300.32 crore.
- SBI Mutual Fund's holding in Alkem increased from 2.16% to 2.7% after the stake purchase.
- Simultaneously, the Samprada & Nanhamati Singh Family Trust, related to Alkem promoters, sold the same number of shares.

Stocks To Buy Today: Ashok Leyland, BSE, Bharti Airtel, Alkem Laboratories, SRF
- Analysts recommend buying stocks of Ashok Leyland, BSE, Bharti Airtel, Alkem Laboratories, and SRF.
- Ashok Leyland stock is advised to be purchased at Rs 218 with a target of Rs 247 and a stop loss of Rs 197.
- BSE stock is recommended to be purchased at Rs 5,339 with a target of Rs 5,540 and a stop loss of Rs 5,225.
- Bharti Airtel stock is advised to be purchased at Rs 1,711 with a target of Rs 1,785 and a stop loss of Rs 1,675.

Cummins, Aurobindo, Alkem Labs, Bajaj Electricals, HG Infra, PSP Projects, NOCIL Q3 Review — HDFC Securities
- The brokerage recommends 'Buy' rating on Cummins, HG Infra, Bajaj Electricals, and 'Add' on Aurobindo, Alkem Labs, PSP Projects, NOCIL
- Cummins has multiple tailwinds, namely, stringent emission norms, capex cycle recovery, adoption of alternative fuels with lower carbon footprint, revival in industrials and exports, and support for manufacturing policies. We maintain Buy, with a revised SOTP of Rs 4,597 (54x Dec-26 EPS).

Q3 Results Today: LIC, NHPC, Ola Electric, Mazagon Dock, Delhivery, M&M Among 230+ Firms To Declare Earnings
- A total of 234 companies are set to release their financial results for the quarter ending December 31, 2024.
- Notable companies include LIC India, M&M, Ola Electric, NHPC, Mazagon Dock Shipbuilders and Oil India.
- Other companies include Edelweiss Financial Services, Shipping Corporation of India, Sun TV, Balrampur Chini Mills and Alkem Laboratories.
- State Bank of India reported a remarkable 84% increase YoY in net profit for the October-December quarter, while Bharti Airtel's consolidated net profit jumped significantly in the third quarter.
- Both M&M and NHPC have reported their Q3 results where M&M's revenue rose 12% YoY to reach Rs 28,919 crore, while NHPC's consolidated net profit fell by 37%.
- LIC's consolidated net profit for Q2 FY25 fell by 3.7% YoY, reporting Rs 7,729 crore.
- These are among over 200 companies expecting to declare their quarterly results on February 7.
- Other companies scheduled to report results are Balrampur Chini Mills, Bombay Talkies, Cholamandalam Financial Holdings.
- Also, companies like 3M India, B.L.Kashyap and Sons, Elixir Capital Ltd, KPT Industries and Max Estates among others will declare their Q3 results today.
- SBI reported a consolidated net profit of Rs 16,891 crore while Bharti Airtel's consolidated net profit rose four-fold sequentially in the third quarter to reach Rs 14,781.2 crore.

Stocks To Watch: Tata Power, Lupin, RVNL, NLC, ICICI Prudential, Alkem Labs
- Tata Power Co.'s consolidated net profit climbed 8% in the third quarter
- Lupin clarified reports about receiving the US FDA approval for a generic HIV drug, saying they have received tentative approval for their Abbreviated New Drug Application
- ICICI Prudential Life Insurance Co received a show-cause notice demanding Rs 492.06 crore
- Rail Vikas Nigam secured a Rs 404.4-crore contract from East Coast Railway for a road doubling project

Rubicon to raise ₹500 crore via IPO for inorganic growth
- Rubicon Research is planning to raise ₹500 crore through an initial public offering (IPO) to support its inorganic growth strategy.
- The company has a track record of successful acquisitions, including the recent acquisition of Alkem Laboratories' Pithampur facility and Validus Pharmaceuticals LLC.
- Rubicon has a strong presence in the US market, with over 25% market share by volume for 7 out of 55 commercialized products.
- The company operates FDA-inspected facilities in Maharashtra and has a portfolio of 69 approved ANDA and NDA products.

Alkem Laboratories Gets Income Tax Orders Worth Rs 375 Crores
- Alkem Laboratories Ltd. has received income tax orders worth Rs 375 crores for the assessment years 2020-21 and 2022-23.
- The orders have disallowed part of the deduction claims, and Rs 375.14 crores have been disputed by the IT authority.
- No amount is payable due to the utilization of available MAT credit.
- In the second quarter, Alkem Laboratories' net profit rose 14% to Rs 702 crores, led by a two-times increase in other income.

Alkem to transfer trade generics business to subsidiary
- Alkem Laboratories Limited plans to transfer its trade generics business to a subsidiary.
- The transaction involves transferring assets, liabilities, employees, contracts, and other components of the trade generics business.
- The trade generics business contributes approximately ₹1,783.8 crore, representing 18.3% of the company's standalone revenue.
- The move aims to achieve greater business agility, focus on trade generics, and expand market penetration in underserved areas.

Indian Pharma Market Grew 9.9% In November Driven By New Launches, Price Rise
- The Indian pharmaceutical market delivered a growth of 9.9% year-on-year in November 2024 driven by new launches and price rise.
- Except for respiratory and gynaecology, all other top therapies witnessed healthy growth, with derma seeing the highest growth at 15.8%.
- Ind-Ra expects Indian Pharma Market (IPM) growth to be around 8-9% YoY for fiscal 2025, compared to 6.5% YoY in fiscal 2024.
- Leading pharma companies like Alkem Laboratories, Glenmark Pharmaceuticals, Dr. Reddy’s Laboratories, and Torrent Pharmaceuticals demonstrated strong performance.

Manish Kumar takes on CHRO role at Paytm Payments Bank
- Manish Kumar has been appointed chief human resources officer (CHRO), Paytm Payments Bank.
- He has moved from UBI Services, where he was chief people officer.
- Kumar has a vast experience in the field of HR, previously serving in various roles at companies like Reliance Capital, Alkem Laboratories, IDFC Bank, and RBS.
- HRKatha wishes Manish Kumar all the best in his new role at Paytm Payments Bank.

Compare Alkem Laboratories with




















Contribute & help others!
Companies Similar to Alkem Laboratories












Alkem Laboratories FAQs
Reviews
Interviews
Salaries
Users/Month